NEW YORK (GenomeWeb) – Interpace Diagnostics said today that Blue Shield of California has agreed to cover Interpace's combination molecular thyroid tests, ThyGenX and ThyraMir.
Blue Shield of California, which serves more than 4 million health plan members and 65,000 physicians in the state, published positive medical policy coverage for the ThyGenX and ThyraMir assays for thyroid nodules deemed indeterminate by standard cytopathological analysis.